AGM/EGM Notice
GlaxoSmithKline Pharmaceuticals Postal Ballot Notice
GlaxoSmithKline Pharmaceuticals seeks shareholder approval for related party transactions with GSK Biological S.A. of up to ₹630 crore during FY2026-27.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.


Bearish
2
Neutral
7
Bullish
5
Bearish
2
Neutral
7
Bullish
37
Bearish
0
Neutral
0
Bullish
32
Bearish
0
Neutral
0
Bullish
32
Bearish
0
Neutral
0
Bullish
32
Bearish
0
Neutral
0
Bullish
32


Pharmaceuticals & Biotechnology
Pharmaceuticals
45,630 Cr
Low Risk
39.8
39.0
4.2
24.3
3,121.10
2,088.00
Sales CAGR
Profit CAGR
ROE
ROCE
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Glaxosmithkline Pharmaceuticals Ltd (GLAXO) is currently trading at 2,674.45 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes and trades general medicines, vaccines and specialty pharmaceuticals in India, supported by branded products, contract manufacturing, a Nashik manufacturing facility, described Thane operations and a Bangalore clinical development centre. Its prescription portfolio spans anti-infectives, dermatology, respiratory, oncology, gynaecology, cardiovascular disease and other important therapeutic areas. The company delivered record quarterly revenue of INR1,180 crores in Q2 FY27, up 21% year-on-year, although management attributes approximately 12% to 13% to underlying growth after adjusting for a low base, GST-related benefits and prior-year disruption from a contract manufacturing organisation fire. Mid-to-high single-digit volume growth indicates that performance was not solely price-led. Portfolio transformation is becoming measurable: innovation products, comprising oncology, adult vaccines and specialty respiratory, increased to 7% of revenue from approximately 3% a year earlier. Management stated that these assets contributed around one-quarter of total growth, with Shingrix sales doubling year-on-year and Jemperli and Zejula gaining momentum after their first full year of market presence. The company remains financially resilient while investing in growth. Q2 EBITDA rose 20% to INR400 crores, with margins maintained near 34%, cash conversion at 98%, no debt and approximately INR2,200 crores of cash. However, gross margin declined 120 basis points because of currency and oil-linked input cost pressure, partly offset by operating leverage. GSK India is entering a more launch-intensive phase, with Blenrep expected in the December quarter for multiple myeloma and Bepirovirsen or Hibsago potentially entering hepatology within the next twelve months, subject to Indian approvals. Management believes the established portfolio can grow at high single digits while specialty launches lift blended growth toward approximately 12% to 13%.
Over the past 52 weeks, Glaxosmithkline Pharmaceuticals Ltd has traded between a low of ₹2,088.00 and a high of ₹3,121.10. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Glaxosmithkline Pharmaceuticals Ltd has a market capitalization of approximately 45,630.36. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Glaxosmithkline Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 39.80 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 45,630.36 Cr, Glaxosmithkline Pharmaceuticals Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Glaxosmithkline Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Glaxosmithkline Pharmaceuticals Ltd is 39.80. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
GSK India has identified 2031 as the horizon for its Rs 8,000 crore revenue aspiration. Management did not issue annual revenue guidance or formally adopt the growth-rate calculations proposed by an analyst during the call.
GSK said its innovation portfolio contributed 7% of Q2 FY27 revenue. That was up from about 3% in Q2 FY26, meaning the sales mix more than doubled over the year. The portfolio includes oncology, adult vaccines and specialty respiratory.
GSK India reported 17% growth for chronic therapies and 13% for acute therapies, but did not provide separate price or volume figures for those segments. The presentation therefore does not identify a specific cause for chronic therapies' four-percentage-point lead.
GSK reported standalone Q2 FY27 revenue of Rs 1,180 crore, up 21% year on year. H1 FY27 revenue was Rs 2,104 crore, an increase of 18%. The quarter therefore grew 3 percentage points faster than the first half.